SAN DIEGO, Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointments of Dr. J.
Clayburn La Force, Jr., and Dr. Duke K. Bristow to the company's Board of
Directors. The new directors have been appointed to fill the vacancies created
by the resignations of Dr. John P. McAlister I...
SAN DIEGO, Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) (Arena) announced today that it has entered
into a multi-year research and licensing agreement with Merck & Co., Inc.
(Merck) to collaborate on validating and developing therapeutics on three orphan
G protein-coupled receptors (GPCRs) of ...
SAN DIEGO, Sep 30, 2002 (BUSINESS WIRE) -- Arena Pharmaceuticals, Inc. (Nasdaq:
ARNA), announced today that it will host both a telephone and internet third
quarter conference call on Tuesday, October 29, 2002 at 4:30 p.m. Eastern Time
(1:30 p.m. San Diego Time). The Company will release financial results for the
third quarter that afternoon af...
SAN DIEGO, Jul 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $5.8 million for
the quarter ended June 30, 2002, a 75% increase over second quarter 2001
revenues of $3.3 million, and $10.1 million for the six months ended June 30,
2002, a 15% increase over the six months ended ...
SAN DIEGO, Jul 3, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a
telephone and internet second quarter conference call on Tuesday, July 23, 2002
at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). The Company will release
financial results for the second quarter th...
SAN DIEGO, May 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of a
research and license agreement with Ferring Pharmaceuticals, Inc. (Ferring), a
unit of privately-held Ferring Holding S.A., a biopharmaceutical company with
operations in 35 countries and products di...
SAN DIEGO, Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $4.2 million for
the quarter ended March 31, 2002, versus $5.4 million in revenues for the
quarter ended March 31, 2001. Revenues in the first quarter of 2002 and 2001
were attributable to collaborations, which incl...
SAN DIEGO, Apr 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a
telephone and internet first quarter conference call on Wednesday, April 24,
2002 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time).
Jack Lief, president and chief executive officer, and Joseph ...
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported record revenues of $5.9 million for the quarter
ended December 31, 2001, a 44% increase over fourth quarter 2000 revenues, and
$18.1 million for the full year ended December 31, 2001, a 135% increase over
the full year ended December 31, 2000....
SAN DIEGO, Jan 3, 2002 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will host both a telephone and internet
fourth quarter conference call on Thursday, January 17, 2002 at 4:30 p.m.
Eastern Time (1:30 p.m. San Diego Time).
Jack Lief, president and chief executive officer, and Joseph Mooney, ...
SAN DIEGO, Nov. 7 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it has completed its initial analysis of
human G protein-coupled receptor (GPCR) gene expression in 80 normal human
tissues. Utilizing a proprietary, custom-designed, oligonucleotide
"GPCR chip," Arena has identified relative expression l...
SAN DIEGO, Oct. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $3.5 million for the quarter ended
September 30, 2001, a 50% increase over third quarter 2000 revenues, and
$12.2 million for the nine months ended September 30, 2001, a 238% increase
over the nine months ended September 30, 2000. ...
SAN DIEGO, Oct 2, 2001 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will host both a telephone and internet
third quarter conference call on Thursday, October 18, 2001 at 4:30 p.m. Eastern
Time (1:30 p.m. San Diego Time).
Jack Lief, president and chief executive officer, and Joseph Mooney, c...
SAN DIEGO, Aug 31, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will host both a telephone and internet
conference call on Wednesday September 5, 2001 at 4:15 p.m. Eastern Time (1:15
p.m. San Diego Time).
Jack Lief, president and chief executive officer, and Joseph Mooney, chief
financial officer...
SAN DIEGO, Aug 20, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA); ("Arena") today announced the signing of a license agreement
with TaiGen Biotechnology Co., Ltd. ("TaiGen"), a privately-held
biopharmaceutical organization located in Taipei, Taiwan. Under the terms of the
agreement, TaiGen has the right to select validated scr...
SAN DIEGO, Jul 23, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $3.3 million for the quarter ended
June 30, 2001, a 158% increase over second quarter 2000 revenues, and $8.7
million for the six months ended June 30, 2001, a 576% increase over the six
months ended June 30, 2000. Increased revenues in...
SAN DIEGO, July 9 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it has entered into an agreement with the
ICI group to apply Arena's proprietary CART technology to olfactory and
gustatory G protein-coupled receptors (GPCRs). The initial stage of the
research will last at least six months and Arena int...
SAN DIEGO, Jul 5, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will host both a telephone and internet
second quarter conference call on Monday, July 23, 2001 at 4:30 p.m. Eastern
Time (1:30 p.m. San Diego Time).
Jack Lief, president and chief executive officer, and Joseph Mooney, chief
financial...
SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the underwriting group managed by Thomas
Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard
Freres & Co. LLC., have exercised their over-allotment option in connection with
Arena's June 21, 2001 secondary offeri...
SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares
of its common stock was priced on June 21, 2001 at $27.50 per share. Of the
5,000,000 shares, Arena offered 4,000,000 shares and two selling stockholders
offered a total 1,000,000 shares. Arena...
